The regulatory framework for new medicines in Australia

Every medicine you can fill at an Australian pharmacy has been through a regulatory process. Most of it happens invisibly to patients, but it shapes a lot of what’s available, when, and on what terms. This page explains the broad shape of how Australia regulates new medicines — who does the work, what they’re checking, and what the structure is designed to balance.

The regulator

The body responsible for regulating medicines in Australia is the Therapeutic Goods Administration (TGA), part of the federal Department of Health and Aged Care. The TGA’s remit covers prescription medicines, over-the-counter medicines, complementary medicines, medical devices, and some other therapeutic goods.

The TGA works alongside other parts of the health system — the Pharmaceutical Benefits Advisory Committee (PBAC) for subsidy decisions, the Department of Health for policy, the Medical Board for prescriber regulation, and the Pharmacy Board for pharmacist regulation. But the TGA is the body responsible for deciding whether a medicine can legally be supplied in Australia, and on what terms.

What the TGA evaluates

When a new prescription medicine is proposed for the Australian market, the sponsor (typically the manufacturer or its Australian arm) submits an application to the TGA. The application includes data covering three core areas:

Quality. How the medicine is made, how consistent it is from batch to batch, how it’s tested, what the manufacturing standards are, and how stability has been demonstrated.

Safety. What the medicine does in the body, what the side effect profile looks like across the clinical trial population, what risks have been identified, what patient groups need additional care, and what monitoring is recommended.

Efficacy. Whether the medicine actually does what it’s claimed to do, in the conditions for which approval is being sought. This is where the clinical trial data sits — typically including comparisons with placebo, with existing treatments, or both, in the relevant patient population.

The TGA’s evaluators — pharmacologists, toxicologists, statisticians, clinicians and other experts — work through the data in detail. The process isn’t a rubber stamp; it’s a structured technical review by people whose job is to find problems if they exist.

The pathways

Not all medicines go through the same approval route. The TGA has several pathways:

Standard registration. The default route for new prescription medicines. Full data submission, full TGA evaluation, typical timeframes of 9–18 months once the application is complete.

Priority review. A faster route for medicines that meet criteria for serious or life-threatening conditions with high unmet need. The data requirements are the same; the timeframes are shorter due to higher prioritisation of the evaluation work.

Provisional registration. A pathway introduced in 2018 for medicines that show promising efficacy in serious conditions but where confirmatory long-term data isn’t yet complete. Provisional approval allows access to patients sooner, with a requirement that the sponsor complete and submit confirmatory data within a specified period (usually six years) for full registration.

Comparable Overseas Regulator (COR) pathway. A streamlined route that uses evaluation work already done by recognised overseas regulators (FDA, EMA, MHRA, Health Canada, Swissmedic), while still applying Australian regulatory requirements. This can shorten timelines for medicines that have already been thoroughly evaluated elsewhere.

Orphan drug designation. Special considerations for medicines treating rare conditions, including reduced fees and potentially streamlined evaluation.

Each pathway has specific criteria, and the choice of pathway is made in consultation between the sponsor and the TGA.

What approval means — and doesn’t mean

When the TGA approves a new medicine for registration on the ARTG, it has formed a view that:

• The medicine’s safety, quality and efficacy data support its approval for the proposed indications
• The benefits outweigh the risks for the intended patient group, when used as approved
• The product information accurately describes the medicine, its uses, its risks, and how it should be used
• Manufacturing meets Australian standards

Approval doesn’t mean:

• The medicine is subsidised (that’s a separate PBAC decision)
• It’s the best option for every patient (that’s a clinical decision for the prescriber)
• It’s without risks (every medicine has risks; the question is whether they’re acceptable in the context of the benefits)
• It can be promoted to the public for those indications (advertising of prescription medicines to consumers is heavily restricted in Australia)
• It will be available indefinitely (ongoing monitoring can lead to label changes, scheduling changes, or withdrawal)

Ongoing monitoring after approval

Approval is the start of the regulatory life cycle, not the end.

Once a medicine is registered, the TGA monitors it through:

• Adverse event reporting — clinicians, pharmacists, sponsors and the public can report unexpected or serious side effects, and the TGA analyses patterns over time
• Periodic Safety Update Reports — sponsors submit summaries at regular intervals
• Risk Management Plans — for higher-risk medicines, formal plans exist for monitoring specific risks
• Targeted reviews — when new safety information emerges, the TGA can launch focused reviews
• Black Triangle Scheme — newly approved medicines are flagged for enhanced reporting in their first few years on the market

This ongoing monitoring can lead to product information updates, dose changes, restrictions, scheduling changes, or in some cases, withdrawal from the market.

How Australia compares internationally

Australia’s regulatory framework is broadly aligned with comparable countries — the United States (FDA), Europe (EMA), the United Kingdom (MHRA), Canada (Health Canada) — but with its own structures and decisions.

A few features worth noting:

Australia is often not the first to approve a new medicine. Initial approvals frequently happen in the US or Europe, with Australian approval following months or years later. This is partly a function of market size and where sponsors prioritise submissions.

Australian approvals can use overseas work. The Comparable Overseas Regulator pathway means Australia doesn’t necessarily redo every piece of evaluation from scratch — but the final decision is Australia’s, and Australian standards apply.

The PBS adds a second layer. Even after TGA approval, a medicine isn’t subsidised until the PBAC recommends listing and government accepts. This means there can be a gap between when a medicine becomes legally available in Australia and when it becomes affordably available through the PBS.

Advertising rules are stricter. Australia restricts direct-to-consumer advertising of prescription medicines (unlike the US, where it’s allowed under specific rules). Prescription medicines can be promoted to health professionals but not to the general public.

What this means for you

For most patients, the regulatory framework is invisible — you see a health practitioner, you fill the prescription, you take the medicine. But understanding the broad outline helps when:

• A medicine you’ve been on has its label updated or its scheduling changed
• A new medicine becomes available and you’re trying to understand where it sits in the system
• You’re considering treatment options and want to know what evidence supports each
• You hear about a medicine available overseas that isn’t yet approved here
• You’re trying to evaluate health claims you’ve encountered online or in marketing

In each of those situations, knowing that there’s a structured regulatory framework underneath — and roughly what it covers — makes the conversation a lot more navigable.

The framework isn’t perfect, and there’s ongoing debate about timeframes, access, costs and other aspects. But it does mean that the medicines on Australian pharmacy shelves have been through a meaningful process, and there’s a system in place to keep monitoring them once they’re there.

That’s a useful foundation to have in mind, whatever the specific medicine or condition.